Pharmacological properties of nateglinide, rapid-onset/short-duration insulinotropic agent, in the treatment of Type 2 diabetes

Folia Pharmacologica Japonica

Volumn 116, Issue 3, 2000, Pages 171-180

  Ikenoue, T ^a   Kondo, N ^a  

^a AJINOMOTO CO INC   (Japan)

Author keywords

Early phase insulin secretion; Nateglinide; Postprandial hyperglycemia; Rapid onset short duration insulinotropic agent; Type 2 diabetes

Indexed keywords

DIAZOXIDE; GLIBENCLAMIDE; GLICLAZIDE; NATEGLINIDE; NITRENDIPINE; PHENYLALANINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POSTPRANDIAL STATE; REVIEW;

EID: 0033778830     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.116.171     Document Type: Review

References (36)

1. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
4. Sulfonylureas in NIDDM
5. Glyburide enhances the responsiveness of the β-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus
6. Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: A dose-response study
7. N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agents
8. N-(Cyclohexylcarbonyl)-D-phenylalanines and related compounds. A new class of oral hypoglycemic agents. 2
9. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agent, (-) -N- (trans- 4 -isopropylcyclohexane-carbonyl) -D-phenylalanine (A-4166)
10. 2+ influx
11. A new hypoglycemic agent, A-4166, inhibits ATP-sensitive potassium channels in rat pancreatic β-cells
12. Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreas
13. Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family
14. Drug-induced hypoglycemia
15. Effect of A-4166 on postprandial hyperglycemia in GK rats
16. α-Glucosidase inhibitors as agents in the treatment of diabetes
17. Effect of a new hypoglycemic agent, A-4166 [ (-) -N- (trans-4-isopropylcyclohexanecarbonyl) -D-phenylalanine], on postprandial blood glucose excursion: Comparison with voglibose and glibenclamide
18. Chronic exposure to glibenclamide impairs insulin secretion in isolated rat pancreatic islets
19. Glyburide and tolbutamide induce desensitization of insulin release in rat pancreatic islets by different mechanisms
20. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: Evidence supporting specific desensitization rather than β-cell exhaustion
21. 2+ regulation prevail over changes in insulin content
22. Selective unresponsiveness of pancreatic β-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM
23. Characteristics of noninsulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy
24. + channel activity
25. Glucose and tolbutamide induce apoptosis in pancreatic β-cells
26. Hypoglycaemic action of phenylalanine derivatives
27. 2+ in pancreatic β-cells under metabolic inhibition
28. + channel block by sulfonylurea in pancreatic β-cells
29. Studies on the N - [(trans-4-isopropylcyclohexyl) -carbonyl] -D-phenylalanine (A-4166) receptor in HIT T-15 cells